Edition:
India

Enochian Biosciences Inc (ENOB.OQ)

ENOB.OQ on NASDAQ Stock Exchange Capital Market

4.69USD
1:30am IST
Change (% chg)

$0.06 (+1.30%)
Prev Close
$4.63
Open
$4.75
Day's High
$4.86
Day's Low
$4.61
Volume
7,504
Avg. Vol
17,660
52-wk High
$9.50
52-wk Low
$4.05

Summary

Name Age Since Current Position

Eric Leire

60 2017 Chief Executive Officer

Mark Dybul

2019 Executive Vice Chairman of the Board

Luisa Puche

55 2019 Chief Financial Officer

Robert Wolfe

55 2019 Principal Accounting Officer, Chief Accounting Officer

Luc Debruyne

2018 Director

Henrik Gronfeldt-Sorensen

2017 Director

Jacob Rosenberg

51 2014 Director

Rene Sindlev

2017 Director

Biographies

Name Description

Eric Leire

Dr. Eric Jean Marie Patterson Leire, M.D., is Chief Executive Officer of the Company. From April of 2011 until April of 2017, Dr. Leire served as the Chief Executive Officer and a director of DanDrit Biotech A/S, the Company’s operating subsidiary He also served as the Chief Executive Officer and a director of the Company from the time of its Merger with DanDrit Biotech A/S in February of 2014 until April of 2017. From September 2012 to September 2014, Dr. Leire served as the Chief Executive Officer and a director of DKTI A/S, a listed Danish investment company from. Prior to these roles Dr. Leire was a partner at Medwell Capital Corp., a Canadian venture fund, from April 2010 through May 2011 and a partner at BioFund Venture Capital, a Finnish biotech venture fund, from August 2006 through September 2010. Dr. Leire has worked globally for many international pharmaceutical organizations, including Schering-Plough, Pfizer, Inc., Boots Pharmaceuticals Company PLC, Harvard AIDS Institute and bioStrategies Group. Dr. Leire has previously served as the CEO of US biotech companies APT Therapeutics and Paringenix and currently serves on the board of directors of Novicol Canada. Dr. Leire received his medical degree from the University of Medicine of Grenoble in 1980 and his MBA from ISA-HEC and the Kellogg School of Management at Northwestern University in 1991.

Mark Dybul

Dr. Mark Dybul is Executive Vice Chairman of the Board of the company. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher, and administrator, currently as the Faculty Co-Director of the Center for Global Health and Quality since June of 2017, previously as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O'Neill Institute for National and Global Health Law from 2009 through 2012. Dr. Dybul was one of the founding architects in the formation of the U.S. President's Emergency Plan for AIDS Relief, better known as PEPFAR. After serving as Chief Medical Officer, Assistant, Deputy and Acting Director, he was appointed as its leader in 2006, becoming U.S. Global AIDS Coordinator, with the rank of Ambassador at the level of an Assistant Secretary of State. He served until early 2009. Earlier in his career, after graduating from Georgetown Medical School in Washington D.C., Dr. Dybul joined the National Institute of Allergy and Infectious Diseases, as a research fellow under director Dr. Anthony Fauci, where he conducted basic and clinical studies on HIV virology, immunology and treatment optimization, including the first randomized, controlled trial with combination antiretroviral therapy in Africa. Dr. Dybul has written extensively in scientific and policy literature, and has received several Honorary Degrees and awards, including a Doctor of Science, Honoris Causa, from Georgetown University and is an active member of the National Academy of Medicine.

Luisa Puche

Ms. Luisa Puche is Chief Financial Officer of the Company. She has worked as a senior accounting and financial advisor and as President of Puche Group, LLC, an audit, regulatory, and corporate advisory consultancy, since 2015. Between 2010 and 2014, Ms. Puche served in various senior executive roles at Brightstar Corp., a global wireless device services provider, including as Vice President and Global Controller and as Interim Chief Accounting Officer. Ms. Puche also previously worked at Ernst and Young, most recently as Associate Director of the Security & Technology Solutions Consulting Practice from 200 through 2004. Ms. Puche holds a BS in Accounting from Florida International University.

Robert Wolfe

Mr. Robert E. Wolfe serves as Principal Accounting Officer, Chief Accounting Officer of the Company. He was Director of the Company. He was Chief Financial Officer, Principal Financial of the Company, since February 2014. Mr. Wolfe has served as the Chief Financial Officer since January 1, 2014. Mr. Wolfe also serves as Chairman and CEO of IProcess Manager Inc. from April 2010, and as a director of Iso-Ware A/S from February 2006. In addition, Mr. Wolfe has served as Chairman, CEO and CFO of Advanced Oxygen Technologies, Inc., a publicly traded company, since December 1997, which owns Anton Nielsen VojensApS, a Danish commercial real estate company. Mr. Wolfe has served as President, CEO and director of Crossfield, Inc., Crossfield Investments, LLC, Drumbeg Ltd, Baldwin Construction Inc. and Ludlow Leasing, Inc. from May 1989 to the present. The Board of Directors believes that Mr. Wolfe’s experience with U.S. public companies and Danish entities qualifies Mr. Wolfe to serve as a director of the Company. On March 13, 2015, the Company, DanDrit Denmark and Mr.Wolfe entered into an Agreement pursuant to which Mr. Wolfe ceased to be Chief Financial Officer of DanDrit Denmark effective as of the date on which a replacement Chief Financial Officer is engaged.

Luc Debruyne

Henrik Gronfeldt-Sorensen

Jacob Rosenberg

Dr. Jacob Rosenberg, M.D., serves as Director of the Company, since February 2014. Dr. Rosenberg currently serves as a director of DanDrit Denmark, a position he has held since May 2012. Prior to this role, Dr. Rosenberg served as Chairman of DanDrit Denmark’s board from 2003 to 2009 and Chairman of T-cellic A/S from 2007 to 2008. Dr. Rosenberg is also currently Chairman of the board of DKTI A/S. Dr. Rosenberg was appointed as a Professor of Surgery at the University of Copenhagen in 2003, where he also received his M.D. in 1991. He also has a D.Sc. from the University of Copenhagen. During the years 1997-2003 he received 6 honorary research prizes. Professor Rosenberg has overseen DanDrit Denmark’s Copenhagen based clinical trials. The Board of Directors believes that Dr. Rosenberg is one of the leading experts in research in cancer and dendritic cells and, as a result, that he has a thorough understanding of our company and our technology.

Rene Sindlev

Basic Compensation